Redcare Pharmacy's Sales Surge 26.4% in Strong Q2 Performance

Redcare Pharmacy N.V. has reported a significant increase in sales for Q2 2025, with total sales rising 26.4% to EUR 709 million, compared to EUR 561 million in the same quarter last year. In the first half of 2025, sales reached EUR 1.4 billion, marking a 27.2% increase. The growth was driven by a strong performance in both non-prescription (Non-Rx) and prescription (Rx) segments.

Non-Rx sales increased by 17% to EUR 457 million in Q2, while Rx sales in Germany surged by 125.1% to EUR 114 million. The total Rx sales for the group rose by 48.1%, attaining EUR 252 million. The company also expanded its customer base by 0.4 million, reaching 13.5 million active customers.

Growth was observed across all regions, including the DACH and International segments. DACH sales surged 26.6% to EUR 574 million, and international sales climbed 25.9% to EUR 135 million. Redcare expects sustained growth and projects its Q2 EBITDA margin to exceed 2%, anticipating further improvements throughout the year.